Les nouveaux anticoagulants oraux directs chez le sujet âgé : point de vue de l’interniste
Tóm tắt
Từ khóa
Tài liệu tham khảo
Wang Y, Bajorek B (2014) New oral anticoagulants in practice: pharmacological and practical considerations. Am J Cardiovasc Drugs 14:175–89
Levy JH, Spyropoulos AC, Samama CM, Douketis J (2014) Direct Oral Anticoagulants: new drugs and new concepts. JACCC ardiovasc Interv 7:1333–51
Lafuente-Lafuente C, Pautas E, Belmin J (2013) Anticoagulation du sujet âgé: nouveautés thérapeutiques. Presse Med 42:187–96
Sardar P, Chatterjee S, Chaudhari S, Lip GY (2014) New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J Am Geriatr Soc 62:857–64
Andrès E, Mourot-Cottet R, Keller O (2015) Patients sous anticoagulationau long cours: phénotype clinique et impact des comorbidités: étude rétrospective de 417 patients. Congrès de la Société française d’hématologie, Paris, 1er au 3 avril 2015
Andrès E, Gaertner S, Mecili M, Stephan D (2012) Amélioration des pratiques dans la prise en charge des thrombophilies et/ou autres thromboses « inhabituelles »: avantages et limites d’une réunion de concertation pluridisciplinaire. Congrès de la Société nationale française de médecine interne de Clermont-Ferrand. Rev Med Interne 33: S122–S3
http://ansm.sante.fr/Dossiers/Anti-vitamine-K-AVK/Prevention-des-hemorragies-provoquees-par-les-traitements-anticoagulants-anti-vitamine-K-AVK/(offset)/0, janvier 2015
Connolly SJ, Ezekowitz MD, Yusuf S, et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–51
Patel MR, Mahaffey KW, Garg J, et al (2011) Rivaroxaban versuswarfarin in nonvalvular atrial fibrillation. N Engl J Med 365:883–91
Granger CB, Alexander JH, McMurray JJ, et al (2011) Apixabanversus warfarin in patients with atrial fibrillation. N Engl J Med 365:981–92
Ruff CT, Giugliano RP, Antman EM, et al (2010) Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effectivea Nticoa Gulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48(ENGAGE AF-TIMI 48). Am Heart J 160:635–41
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al (2010) Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 363:2499–510
EINSTEIN–PE Investigators, Büller HR, Prins MH, et al (2012) Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 366:1287–97
Agnelli G, Buller HR, Cohen A, et al (2013) Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 369:799–808
Hanon O (2013) Novel oral anticoagulants and atrial fibrillation in the elderly. Geriatr Psychol Neuropsychiatr Vieil 11:34–40
Corey S, Miller BA, Sonia M, et al (2012) Meta-analysis of efficacyand safety of new oral anticoagulants (dabigatran, rivaroxaban,apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol 110:453–60
Quélennec B, Beretz L, Paya D, et al (2013) Medication reconciliationat hospital admission: what about the potential clinical impact of unintentional discrepancies? A prospective study in a French Internal Medicine Department. Eur J Intern Med 24:530–5
Vogel T, Geny B, Kaltenbach G, Andrès E (2014) Anticoagulationde la fibrillation atriale par les nouveaux anticoagulants chez la personne âgée: les limites de l’evidence-based medicine. MedTher 20:3–14